Unknown

Dataset Information

Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study.


ABSTRACT: There are plausible mechanisms by which angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may increase the risk of COVID-19 infection or affect disease severity. To examine the association between these medications and COVID-19 infection or hospitalization, we conducted a retrospective cohort study within a US integrated healthcare system. Among people aged ≥18 years enrolled in the health plan for at least 4 months as of 2/29/2020, current ACEI and ARB use was identified from pharmacy data, and the estimated daily dose was calculated and standardized across medications. COVID-19 infections were identified through 6/14/2020 from laboratory and hospitalization data. We used logistic regression to estimate adjusted odds ratios (ORs) and 95% confidence

SUBMITTER: Dublin S 

PROVIDER: S-EPMC7359535 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature